文献速递妇科

帕博利珠单抗联合同步放化疗治疗高危局部晚期宫颈癌的3期随机双盲安慰剂对照ENGOT-cx11/GOG-3047/KEYNOTE-A18研究患者报告结局

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
PubMed 文献 · Gynecol Oncol · 2025-06-30

ENGOT-cx11/GOG-3047/KEYNOTE-A18研究显示,在高危局部晚期宫颈癌患者中,帕博利珠单抗联合同步放化疗较安慰剂显著改善无进展生存期和总生存期;患者报告结局分析纳入1060例随机化参与者中的1008例(95.1%),预设量表组间差异均无意义,表明帕博利珠单抗联合方案未对健康相关生活质量产生负面影响。

要点

  • 预设患者报告结局量表组间差异均无意义,帕博利珠单抗联合方案未对健康相关生活质量产生负面影响。
  • 从基线至第36周,QLQ-C30总体健康状况/生活质量最小二乘均值评分变化组间差异为0.57(95%CI -2.34至3.49)。
  • QLQ-C30躯体功能、QLQ-CX24症状体验和EQ-5D-5L视觉模拟量表的组间差异95%CI均包含0。

核心结论

  • 帕博利珠单抗联合同步放化疗未对高危局部晚期宫颈癌参与者的健康相关生活质量产生负面影响。

研究设计与样本

  • 3期随机双盲安慰剂对照研究ENGOT-cx11/GOG-3047/KEYNOTE-A18(NCT04221945),纳入新诊断高危局部晚期宫颈癌参与者。
  • 参与者按1:1随机接受5个周期帕博利珠单抗200 mg或安慰剂每3周一次联合同步放化疗,随后15个周期帕博利珠单抗400 mg或安慰剂每6周一次。
  • 同步放化疗为5个周期(可选第6剂)顺铂40 mg/m2每周一次加外照射放疗后近距离放疗。
  • 患者报告结局全分析集纳入1060例随机化参与者中的1008例(95.1%)。

主要发现

  • 预设患者报告结局工具均未观察到有意义的组间差异。
  • 从基线至第36周(主要时间点),QLQ-C30总体健康状况/生活质量最小二乘均值评分变化组间差异为0.57(95%CI -2.34至3.49)。
  • QLQ-C30躯体功能组间差异为0.64(95%CI -1.54至2.82),QLQ-CX24症状体验组间差异为0.54(95%CI -1.02至2.09)。
  • EQ-5D-5L视觉模拟量表组间差异为-0.55(95%CI -2.97至1.86)。
  • 随时间变化的经验均值评分变化及评分改善、稳定或恶化的参与者比例在治疗组间相似。

关键数值与推荐

  • 患者报告结局分析未分配α值。
  • 次要患者报告结局终点包括EORTC QLQ-C30总体健康状况/生活质量和躯体功能子量表及EORTC QLQ-CX24症状体验量表;EQ-5D-5L视觉模拟量表为探索性终点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945), pembrolizumab (vs placebo) + concurrent chemoradiotherapy (CCRT) followed by pembrolizumab (vs placebo) significantly improved progression-free survival and overall survival in participants with newly diagnosed, high-risk locally advanced cervical cancer (LACC). We report patient-reported outcomes (PROs) from the study. METHODS: Participants (≥18 years) with high-risk LACC (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA) were randomized 1:1 to 5 cycles of pembrolizumab 200 mg or placebo Q3W plus CCRT, followed by 15 cycles of pembrolizumab 400 mg or placebo Q6W. CCRT was 5 cycles (optional 6th dose) of cisplatin 40 mg/m2 Q1W plus external beam radiotherapy followed by brachytherapy. Secondary PRO endpoints included EORTC QLQ-C30 GHS/QoL and physical functioning subscales and EORTC QLQ-CX24 symptom experience scale; EQ-5D-5L visual analogue scale (VAS) was an exploratory endpoint. No alpha was assigned to the PRO analyses. RESULTS: 1008 (95.1 %) of 1060 randomized participants were included in the PRO full analysis set population. No meaningful between-group differences were observed for any of the prespecified PRO instruments. Between-group differences (95 % CIs) in least-squares mean score changes from baseline to week 36 (primary time point) were 0.57 (-2.34 to 3.49) for QLQ-C30 GHS/QoL, 0.64 (-1.54 to 2.82) for QLQ-C30 physical functioning, 0.54 (-1.02 to 2.09) for QLQ-CX24 symptom experience, and -0.55 (-2.97 to 1.86) for EQ-5D-5L VAS. Empirical mean score changes over time and the proportions of participants whose scores improved, remained stable, or deteriorated over time were similar between treatment arms. CONCLUSIONS: Pembrolizumab+CCRT did not negatively impact participants' health-related quality of life.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Randall L, Xiang Y, Matsumoto T, et al. Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. Gynecol Oncol. 2025. PMID: 40592026. doi:10.1016/j.ygyno.2025.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。